Skip to main content

Table 1 Baseline and clinical characteristics of the MetS subgroups and controls

From: Plasma Lipoprotein-associated Phospholipase A2 in Patients with Metabolic Syndrome and Carotid Atherosclerosis

Variables

Controls

MetS

  

No carotid plaque

With carotid plaque

Number

70

79

39

Sex (male/female)

30/40

35/44

18/21

Age (years)

52.4 ± 8.8

53.8 ± 7.8

55.4 ± 6.6

BMI (kg/m2)

24.49 ± 2.22

28.99 ± 4.05

28.07 ± 3.45

Waist circumference (cm)

84.51 ± 8.05

98.08 ± 10.16

96.45 ± 8.58

Waist-to-hip ratio

0.86 ± 0.05

0.92 ± 0.06

0.93 ± 0.08

Systolic BP (mmHg)

116 ± 10

151 ± 22

152 ± 23

Diastolic BP (mmHg)

77 ± 7

95 ± 14

94 ± 13

Total cholesterol (mmol/L)

4.42 ± 0.78

5.36 ± 1.12

5.55 ± 0.99

Triglyceride (mmol/L)

0.99 ± 0.42

2.34 ± 1.19

2.23 ± 0.94

HDL cholesterol (mmol/L)

1.53 ± 0.33

1.22 ± 0.31

1.25 ± 0.26

LDL cholesterol (mmol/L)

2.82 ± 0.72

3.63 ± 0.88**

4.03 ± 0.99**▲

Glucose (mmol/L)

4.99 ± 0.54

6.37 ± 2.09**

6.76 ± 3.01**

Insulin (uU/mL)

12.15 ± 5.37

21.39 ± 12.09**

19.63 ± 10.20**

HbA1c( % )

4.58 ± 0.32

5.38 ± 1.05

5.57 ± 1.52

HOMA-insulin resistance

2.74 ± 1.38

6.24 ± 4.90**

5.83 ± 3.45**

Mean IMT (mm)

0.51 ± 0.15

0.74 ± 0.11

0.86 ± 0.20▲▲

Max IMT (mm)

0.61 ± 0.52

0.77 ± 0.09

1.87 ± 0.73▲▲

Lp-PLA2 activity

24.14 ± 6.33

29.62 ± 8.98**

34.10 ± 9.51**▲▲

Medifications

   

Aspirin

-

70(88%)

35(91%)

Anti-hypertensive drugs

-

30(38%)

17(43%)

Oral hypoglycaemic drugs

-

9(12%)

4(11%)

Lipid regulating agents

-

9(12%)

5(14%)

  1. Values are mean ± SD; *P < 0.05 and **P < 0.01 compared to control; ▲P < 0.05 and ▲▲P < 0.01 compared to MetS without carotid plaque
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X